Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs
This article was originally published in PharmAsia News
Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.
You may also be interested in...
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services
Creative Funding Options For China; Investors Battle Perception of Home Court Advantage
The growth in available government funding for pharmaceutical companies in China is creating a snowball of investment from domestic and multinational pharma companies more willing to overcome intellectual property concerns
With Pfizer As Cornerstone Investor, Will Shanghai Pharmaceutical Be Largest Pharma IPO Ever?
SHANGHAI - Shanghai Pharmaceutical Holdings Co. Ltd is set for what could be the largest IPO by a pharmaceutical company ever, surpassing Ostuka Holding's $2.4 billion IPO from last year